Sign in
Taking peopleNo phase

Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).

Key facts

Who runs it
Xiamen Cardiovascular Hospital, Xiamen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
112 people, planned
Started
22 Mar 2025
Planned end
22 Apr 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Structural Heart Surgery Assist System
  • Manual MitraClip G4
Record updated
9 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age ≥18 years, regardless of gender
  • Symptomatic moderate-to-severe or greater mitral regurgitation (MR ≥3+) confirmed by transthoracic and/or transesophageal echocardiography (TTE/TEE), with planned transcatheter edge-to-edge repair (TEER):; For degenerative mitral regurgitation (DMR):; -Deemed high-risk for surgical intervention by the heart team:STS score ≥8% for mitral valve replacement (MVR) mortality risk; ≥6% for mitral valve repair mortality risk; OR presence of ≥2 frailty indices (moderate-to-severe frailty); OR anatomical/technical barriers to surgery; OR ≥2 major organ dysfunctions unlikely to improve postoperatively; OR other high-risk factors per heart team assessment.OR patient declines surgery; For functional mitral regurgitation (FMR):; Persistent heart failure symptoms (NYHA Class III/IVa) despite guidelines directed medical therapy (GDMT), revascularization, or cardiac resynchronization therapy (CRT) for 1-3 months; ≥1 hospitalization for heart failure within the past 12 months and/or BNP >150 pg/mL or NT-proBNP >600 pg/mL; Left ventricular ejection fraction (LVEF) ≥20% and ≤50%, with left ventricular end-systolic diameter (LVESD) ≤70 mm
  • Primary regurgitant jet is non-commissural and deemed treatable by the investigator (secondary jets, if present, must be clinically insignificant)
  • Volunteerly provides informed consent, understands the trial objectives, and agrees to comply with follow-up

Who cannot take part

  • Acute myocardial infarction (AMI) within 30 days prior to the procedure
  • Recent CABG, PCI, or TAVR within 30 days prior to the procedure
  • Prior surgical or transcatheter mitral valve repair/replacement
  • Implanted pacemaker, CRT, or ICD within 30 days prior to the procedure
  • Participation in other clinical trials (drug/device) without meeting primary endpoints
  • Rheumatic mitral valve disease
  • Uncorrected active infection
  • Severe right heart dysfunction (e.g., lower extremity edema with elevated jugular venous pressure and hepatomegaly) or severe pulmonary hypertension (echocardiographic systolic pulmonary artery pressure >70 mmHg)
  • Thrombosis in access vessels (e.g., femoral vein, inferior vena cava) impeding catheter advancement
  • Stroke/TIA within 30 days or severe carotid stenosis (>70% by ultrasound)
  • Cardiomyopathies or conditions including hypertrophic, restrictive, or infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis, sarcoidosis), constrictive pericarditis, or active endocarditis
  • End-stage heart failure (ACC/AHA Stage D), post-heart transplant, or listed for transplant
  • Hypersensitivity or contraindications: ntolerance to anticoagulants, antiplatelet agents, or anesthesia, allergy to mitralclip materials (nickel/titanium, cobalt, chromium, polyester), severe contrast allergy precludes intervention
  • Severe left heart dysfunction (LVEF <20%)
  • Severe calcification or thickening in the clip coaptation zone, rendering TEER anatomically unsuitable
  • Intracardiac mass, thrombus, or vegetation on echocardiography
  • Planned tricuspid/aortic valve or major vascular intervention within 30 days post-procedure
  • Hemodynamic instability: Systolic blood pressure <90 mmHg without afterload-reducing agents, cardiogenic shock, requirement for intra-aortic balloon pump (IABP) or hemodynamic support
  • Pregnant or breastfeeding
  • Other contraindications per investigator judgment

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial aims to evaluate the safety and efficacy of the Structural Heart Surgery Assist System in assisting TEER for patients with moderate-to-severe or greater degenerative or functional mitral regurgitation (MR ≥3+). A prospective, multicenter, stratified randomized controlled design with non-inferiority comparison will be used. The experimental group will utilize the Structural Heart Surgery Assist System, while the control group will undergo manual TEER (e.g., MitraClip G4).

The 2 groups in the trial

  • Structural Heart Surgery Assist System-assisted TEER.Treatment being tested

    Treatment: Structural Heart Surgery Assist System

  • Manual TEER (e.g., MitraClip G4).Placebo, for comparison

    Treatment: Manual MitraClip G4

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Stratified Randomized Controlled, Non-Inferiority Clinical Trial to Evaluate the Safety and Efficacy of the Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).
Record updated
9 July 2025